Precision Psychiatry Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Biomarkers (Genetic v/s Protein), By Sample (Blood Based v/s Non-Blood-Based), By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others), By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism, Depression, Others), By End User (Hospital & Clinics, Academic & Research Institutions, Others), By Company and By Region
The global precision psychiatry market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include rise in incidences of mental health and technological advancements, which are bolstering the market growth, globally. Precision psychiatry is new field within precision medicine, which seeks to detect and capitalize on individual differences in biology, environment, lifestyle, and social determinants of health to improve mental health prevention, diagnosis, and treatment. The other factors supporting the market's growth are increasing awareness, growing investments, increase in population, changing lifestyle, decreasing cost of sequencing, increasing adoption of inorganic growth strategies and support from governments for healthcare infrastructure. Also, the high adoption of advanced molecular diagnostic technologies by the researchers to conduct genomic and proteomic analysis associated to the onset and manifestation of psychiatric illnesses are some of the key factors that are projected to bolster the market growth.
Increase in Prevalence of Mental Disorders
Over the past few years, rise in number of people suffering from mild or severe depressive disorders is seen. These mental illness or disorders are basically caused due to chemical, genetic, and anatomical conditions, or psychological origins such as trauma. Thus, to seek better lives for those suffering from mental illness, precision psychiatry is much required, which attributes to the growth of the market, globally. For instance, according to the National Institute of Mental Health, around one in every five U.S. adults suffer from mental illness. Also, in 2020, 25.8% of females were suffering from mental illness.
Increasing Adoption of Inorganic Growth Strategies
Increasing inorganic growth strategies by key players are expected to drive the global precision psychiatry market growth during the forecast period. For instance, in 2021, Alto Neuroscience announced its emergence from stealth with $40 million in funding to advance the largest clinical-stage pipeline of precision psychiatry medicines. Similarly, in 2021, Atai Life Sciences, a biotech company in the psychedelics space, announced the formation of a new subsidiary, called PsyProtix, which is a precision psychiatry company.
Increased demand for Genomics as precision psychiatry
From past few years, genomic technologies have advanced the understanding of neuropsychiatric disorders. Genomics plays a significant part in the diagnosis of several genetic disorders. It has ample scope in precision psychiatry as it can advocate medical management constructed on the genetic face of a person with the help of clinical data and AI. It incorporates DNA sequencing methods, recombinant DNA, and bioinformatics for sequencing, assembling, and analyzing the structure and functions of genomes. Many severe mental illnesses, such as schizophrenia and bipolar disorder, are highly inherited, and have a complex pattern of inheritance. These diseases can be identified by using sequencing technology, which evaluates the rare genetic variants. With the use of sequencing technology, psychiatry can ultimately reshape by predicting disease risk and lead to better understanding of aetiology, prognosis, or treatment response. Moreover, the decrease in cost of sequencing is also a key factor to increase the growth of the market.
Market Segmentation
The global precision psychiatry market is segmented into biomarkers, sample, technology, application, end user, and company. Based on biomarker, the market is divided into genetic and protein. Based on sample, the market is divided into blood-based and non-blood-based. Based on non-blood-based, the market is further divided into saliva, urine, cerebral spinal fluid, and others. Based on technology, the market is divided into sequencing, polymerase chain reaction, microarray, immunoassay, and others. Based on application, the market is divided into Alzheimer’s disease, Parkinson’s disease, autism, depression, and others. Based on end user, the market is divided into hospital & clinics, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rise in incidences of mental illness in the country.
Market Players
Altimate Healthcare, PsyProtix, Inc, Cerebral-Alto Nanoscience, Precision Psychiatric Services, Inc, Tempus Labs, Inc., and Curis AI Inc. are some of the leading companies operating in the market.
Report Scope:
In this report, global precision psychiatry market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in precision psychiatry market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Increase in Prevalence of Mental Disorders
Over the past few years, rise in number of people suffering from mild or severe depressive disorders is seen. These mental illness or disorders are basically caused due to chemical, genetic, and anatomical conditions, or psychological origins such as trauma. Thus, to seek better lives for those suffering from mental illness, precision psychiatry is much required, which attributes to the growth of the market, globally. For instance, according to the National Institute of Mental Health, around one in every five U.S. adults suffer from mental illness. Also, in 2020, 25.8% of females were suffering from mental illness.
Increasing Adoption of Inorganic Growth Strategies
Increasing inorganic growth strategies by key players are expected to drive the global precision psychiatry market growth during the forecast period. For instance, in 2021, Alto Neuroscience announced its emergence from stealth with $40 million in funding to advance the largest clinical-stage pipeline of precision psychiatry medicines. Similarly, in 2021, Atai Life Sciences, a biotech company in the psychedelics space, announced the formation of a new subsidiary, called PsyProtix, which is a precision psychiatry company.
Increased demand for Genomics as precision psychiatry
From past few years, genomic technologies have advanced the understanding of neuropsychiatric disorders. Genomics plays a significant part in the diagnosis of several genetic disorders. It has ample scope in precision psychiatry as it can advocate medical management constructed on the genetic face of a person with the help of clinical data and AI. It incorporates DNA sequencing methods, recombinant DNA, and bioinformatics for sequencing, assembling, and analyzing the structure and functions of genomes. Many severe mental illnesses, such as schizophrenia and bipolar disorder, are highly inherited, and have a complex pattern of inheritance. These diseases can be identified by using sequencing technology, which evaluates the rare genetic variants. With the use of sequencing technology, psychiatry can ultimately reshape by predicting disease risk and lead to better understanding of aetiology, prognosis, or treatment response. Moreover, the decrease in cost of sequencing is also a key factor to increase the growth of the market.
Market Segmentation
The global precision psychiatry market is segmented into biomarkers, sample, technology, application, end user, and company. Based on biomarker, the market is divided into genetic and protein. Based on sample, the market is divided into blood-based and non-blood-based. Based on non-blood-based, the market is further divided into saliva, urine, cerebral spinal fluid, and others. Based on technology, the market is divided into sequencing, polymerase chain reaction, microarray, immunoassay, and others. Based on application, the market is divided into Alzheimer’s disease, Parkinson’s disease, autism, depression, and others. Based on end user, the market is divided into hospital & clinics, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rise in incidences of mental illness in the country.
Market Players
Altimate Healthcare, PsyProtix, Inc, Cerebral-Alto Nanoscience, Precision Psychiatric Services, Inc, Tempus Labs, Inc., and Curis AI Inc. are some of the leading companies operating in the market.
Report Scope:
In this report, global precision psychiatry market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
- Precision Psychiatry Market, By Biomarker:
- Genetic
- Protein
- Precision Psychiatry Market, By Sample:
- Blood Based
- Non-Blood-Based
- Saliva
- Urine
- Cerebral Spinal Fluid
- Others
- Precision Psychiatry Market, By Technology:
- Sequencing
- Polymerase Chain Reaction
- Microarray
- Immunoassay
- Others
- Precision Psychiatry Market, By Application:
- Alzheimer’s Disease
- Parkinson’s Disease
- Autism
- Depression
- Others
- Precision Psychiatry Market, By End User:
- Hospital & Clinics
- Academic & Research Institutions
- Others
- Precision Psychiatry Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Europe & CIS
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in precision psychiatry market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. IMPACT OF COVID-19 ON GLOBAL PRECISION PSYCHIATRY MARKET
5. VOICE OF CUSTOMER
6. GLOBAL PRECISION PSYCHIATRY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Biomarkers (Genetic v/s Protein)
6.2.2. By Sample (Blood Based v/s Non-Blood-Based)
6.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
6.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
6.2.4. By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism, Depression, Others)
6.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
6.2.6. By Company (2021)
6.2.7. By Region
6.3. Product Market Map
7. NORTH AMERICA PRECISION PSYCHIATRY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Biomarkers (Genetic v/s Protein)
7.2.2. By Sample (Blood Based v/s Non-Blood-Based)
7.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
7.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
7.2.4. By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism, Depression, Others)
7.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
7.2.6. By Country
7.3. North America: Country Analysis
7.3.1. United States Precision Psychiatry Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Biomarker
7.3.1.2.2. By Sample
7.3.1.2.3. By Technology
7.3.1.2.4. By Application
7.3.1.2.5. By End User
7.3.2. Mexico Precision Psychiatry Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Biomarker
7.3.2.2.2. By Sample
7.3.2.2.3. By Technology
7.3.2.2.4. By Application
7.3.2.2.5. By End User
7.3.3. Canada Precision Psychiatry Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Biomarker
7.3.3.2.2. By Sample
7.3.3.2.3. By Technology
7.3.3.2.4. By Application
7.3.3.2.5. By End User
8. EUROPE PRECISION PSYCHIATRY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Biomarkers (Genetic v/s Protein)
8.2.2. By Sample (Blood Based v/s Non-Blood-Based)
8.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
8.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
8.2.4. By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism, Depression, Others)
8.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
8.2.6. By Country
8.3. Europe: Country Analysis
8.3.1. France Precision Psychiatry Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Biomarker
8.3.1.2.2. By Sample
8.3.1.2.3. By Technology
8.3.1.2.4. By Application
8.3.1.2.5. By End User
8.3.2. Germany Precision Psychiatry Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Biomarker
8.3.2.2.2. By Sample
8.3.2.2.3. By Technology
8.3.2.2.4. By Application
8.3.2.2.5. By End User
8.3.3. United Kingdom Precision Psychiatry Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Biomarker
8.3.3.2.2. By Sample
8.3.3.2.3. By Technology
8.3.3.2.4. By Application
8.3.3.2.5. By End User
8.3.4. Italy Precision Psychiatry Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Biomarker
8.3.4.2.2. By Sample
8.3.4.2.3. By Technology
8.3.4.2.4. By Application
8.3.4.2.5. By End User
8.3.5. Spain Precision Psychiatry Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Biomarker
8.3.5.2.2. By Sample
8.3.5.2.3. By Technology
8.3.5.2.4. By Application
8.3.5.2.5. By End User
9. ASIA-PACIFIC PRECISION PSYCHIATRY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Biomarkers (Genetic v/s Protein)
9.2.2. By Sample (Blood Based v/s Non-Blood-Based)
9.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
9.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
9.2.4. By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism, Depression, Others)
9.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
9.2.6. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Precision Psychiatry Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Biomarker
9.3.1.2.2. By Sample
9.3.1.2.3. By Technology
9.3.1.2.4. By Application
9.3.1.2.5. By End User
9.3.2. India Precision Psychiatry Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Biomarker
9.3.2.2.2. By Sample
9.3.2.2.3. By Technology
9.3.2.2.4. By Application
9.3.2.2.5. By End User
9.3.3. South Korea Precision Psychiatry Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Biomarker
9.3.3.2.2. By Sample
9.3.3.2.3. By Technology
9.3.3.2.4. By Application
9.3.3.2.5. By End User
9.3.4. Japan Precision Psychiatry Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Biomarker
9.3.4.2.2. By Sample
9.3.4.2.3. By Technology
9.3.4.2.4. By Application
9.3.4.2.5. By End User
9.3.5. Australia Precision Psychiatry Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Biomarker
9.3.5.2.2. By Sample
9.3.5.2.3. By Technology
9.3.5.2.4. By Application
9.3.5.2.5. By End User
10. SOUTH AMERICA PRECISION PSYCHIATRY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Biomarkers (Genetic v/s Protein)
10.2.2. By Sample (Blood Based v/s Non-Blood-Based)
10.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
10.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
10.2.4. By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism, Depression, Others)
10.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Precision Psychiatry Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Biomarker
10.3.1.2.2. By Sample
10.3.1.2.3. By Technology
10.3.1.2.4. By Application
10.3.1.2.5. By End User
10.3.2. Argentina Precision Psychiatry Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Biomarker
10.3.2.2.2. By Sample
10.3.2.2.3. By Technology
10.3.2.2.4. By Application
10.3.2.2.5. By End User
10.3.3. Colombia Precision Psychiatry Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Biomarker
10.3.3.2.2. By Sample
10.3.3.2.3. By Technology
10.3.3.2.4. By Application
10.3.3.2.5. By End User
11. MIDDLE EAST AND AFRICA PRECISION PSYCHIATRY MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Biomarkers (Genetic v/s Protein)
11.2.2. By Sample (Blood Based v/s Non-Blood-Based)
11.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
11.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
11.2.4. By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism, Depression, Others)
11.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
11.2.6. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Precision Psychiatry Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Biomarker
11.3.1.2.2. By Sample
11.3.1.2.3. By Technology
11.3.1.2.4. By Application
11.3.1.2.5. By End User
11.3.2. Saudi Arabia Precision Psychiatry Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Biomarker
11.3.2.2.2. By Sample
11.3.2.2.3. By Technology
11.3.2.2.4. By Application
11.3.2.2.5. By End User
11.3.3. UAE Precision Psychiatry Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Biomarker
11.3.3.2.2. By Sample
11.3.3.2.3. By Technology
11.3.3.2.4. By Application
11.3.3.2.5. By End User
11.3.4. Egypt Precision Psychiatry Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Biomarker
11.3.4.2.2. By Sample
11.3.4.2.3. By Technology
11.3.4.2.4. By Application
11.3.4.2.5. By End User
11.3.5. Turkey Precision Psychiatry Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1. By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1. By Biomarker
11.3.5.2.2. By Sample
11.3.5.2.3. By Technology
11.3.5.2.4. By Application
11.3.5.2.5. By End User
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
14. COMPETITIVE LANDSCAPE
14.1. Altimate Healthcare
14.2. PsyProtix, Inc
14.3. Cerebral-Alto Nanoscience
14.4. Precision Psychiatric Services, Inc
14.5. Tempus Labs, Inc.
14.6. Curis AI Inc.
15. STRATEGIC RECOMMENDATIONS
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. IMPACT OF COVID-19 ON GLOBAL PRECISION PSYCHIATRY MARKET
5. VOICE OF CUSTOMER
6. GLOBAL PRECISION PSYCHIATRY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Biomarkers (Genetic v/s Protein)
6.2.2. By Sample (Blood Based v/s Non-Blood-Based)
6.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
6.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
6.2.4. By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism, Depression, Others)
6.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
6.2.6. By Company (2021)
6.2.7. By Region
6.3. Product Market Map
7. NORTH AMERICA PRECISION PSYCHIATRY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Biomarkers (Genetic v/s Protein)
7.2.2. By Sample (Blood Based v/s Non-Blood-Based)
7.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
7.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
7.2.4. By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism, Depression, Others)
7.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
7.2.6. By Country
7.3. North America: Country Analysis
7.3.1. United States Precision Psychiatry Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Biomarker
7.3.1.2.2. By Sample
7.3.1.2.3. By Technology
7.3.1.2.4. By Application
7.3.1.2.5. By End User
7.3.2. Mexico Precision Psychiatry Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Biomarker
7.3.2.2.2. By Sample
7.3.2.2.3. By Technology
7.3.2.2.4. By Application
7.3.2.2.5. By End User
7.3.3. Canada Precision Psychiatry Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Biomarker
7.3.3.2.2. By Sample
7.3.3.2.3. By Technology
7.3.3.2.4. By Application
7.3.3.2.5. By End User
8. EUROPE PRECISION PSYCHIATRY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Biomarkers (Genetic v/s Protein)
8.2.2. By Sample (Blood Based v/s Non-Blood-Based)
8.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
8.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
8.2.4. By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism, Depression, Others)
8.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
8.2.6. By Country
8.3. Europe: Country Analysis
8.3.1. France Precision Psychiatry Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Biomarker
8.3.1.2.2. By Sample
8.3.1.2.3. By Technology
8.3.1.2.4. By Application
8.3.1.2.5. By End User
8.3.2. Germany Precision Psychiatry Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Biomarker
8.3.2.2.2. By Sample
8.3.2.2.3. By Technology
8.3.2.2.4. By Application
8.3.2.2.5. By End User
8.3.3. United Kingdom Precision Psychiatry Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Biomarker
8.3.3.2.2. By Sample
8.3.3.2.3. By Technology
8.3.3.2.4. By Application
8.3.3.2.5. By End User
8.3.4. Italy Precision Psychiatry Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Biomarker
8.3.4.2.2. By Sample
8.3.4.2.3. By Technology
8.3.4.2.4. By Application
8.3.4.2.5. By End User
8.3.5. Spain Precision Psychiatry Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Biomarker
8.3.5.2.2. By Sample
8.3.5.2.3. By Technology
8.3.5.2.4. By Application
8.3.5.2.5. By End User
9. ASIA-PACIFIC PRECISION PSYCHIATRY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Biomarkers (Genetic v/s Protein)
9.2.2. By Sample (Blood Based v/s Non-Blood-Based)
9.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
9.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
9.2.4. By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism, Depression, Others)
9.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
9.2.6. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Precision Psychiatry Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Biomarker
9.3.1.2.2. By Sample
9.3.1.2.3. By Technology
9.3.1.2.4. By Application
9.3.1.2.5. By End User
9.3.2. India Precision Psychiatry Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Biomarker
9.3.2.2.2. By Sample
9.3.2.2.3. By Technology
9.3.2.2.4. By Application
9.3.2.2.5. By End User
9.3.3. South Korea Precision Psychiatry Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Biomarker
9.3.3.2.2. By Sample
9.3.3.2.3. By Technology
9.3.3.2.4. By Application
9.3.3.2.5. By End User
9.3.4. Japan Precision Psychiatry Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Biomarker
9.3.4.2.2. By Sample
9.3.4.2.3. By Technology
9.3.4.2.4. By Application
9.3.4.2.5. By End User
9.3.5. Australia Precision Psychiatry Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Biomarker
9.3.5.2.2. By Sample
9.3.5.2.3. By Technology
9.3.5.2.4. By Application
9.3.5.2.5. By End User
10. SOUTH AMERICA PRECISION PSYCHIATRY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Biomarkers (Genetic v/s Protein)
10.2.2. By Sample (Blood Based v/s Non-Blood-Based)
10.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
10.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
10.2.4. By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism, Depression, Others)
10.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Precision Psychiatry Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Biomarker
10.3.1.2.2. By Sample
10.3.1.2.3. By Technology
10.3.1.2.4. By Application
10.3.1.2.5. By End User
10.3.2. Argentina Precision Psychiatry Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Biomarker
10.3.2.2.2. By Sample
10.3.2.2.3. By Technology
10.3.2.2.4. By Application
10.3.2.2.5. By End User
10.3.3. Colombia Precision Psychiatry Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Biomarker
10.3.3.2.2. By Sample
10.3.3.2.3. By Technology
10.3.3.2.4. By Application
10.3.3.2.5. By End User
11. MIDDLE EAST AND AFRICA PRECISION PSYCHIATRY MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Biomarkers (Genetic v/s Protein)
11.2.2. By Sample (Blood Based v/s Non-Blood-Based)
11.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
11.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
11.2.4. By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism, Depression, Others)
11.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
11.2.6. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Precision Psychiatry Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Biomarker
11.3.1.2.2. By Sample
11.3.1.2.3. By Technology
11.3.1.2.4. By Application
11.3.1.2.5. By End User
11.3.2. Saudi Arabia Precision Psychiatry Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Biomarker
11.3.2.2.2. By Sample
11.3.2.2.3. By Technology
11.3.2.2.4. By Application
11.3.2.2.5. By End User
11.3.3. UAE Precision Psychiatry Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Biomarker
11.3.3.2.2. By Sample
11.3.3.2.3. By Technology
11.3.3.2.4. By Application
11.3.3.2.5. By End User
11.3.4. Egypt Precision Psychiatry Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Biomarker
11.3.4.2.2. By Sample
11.3.4.2.3. By Technology
11.3.4.2.4. By Application
11.3.4.2.5. By End User
11.3.5. Turkey Precision Psychiatry Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1. By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1. By Biomarker
11.3.5.2.2. By Sample
11.3.5.2.3. By Technology
11.3.5.2.4. By Application
11.3.5.2.5. By End User
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
14. COMPETITIVE LANDSCAPE
14.1. Altimate Healthcare
14.2. PsyProtix, Inc
14.3. Cerebral-Alto Nanoscience
14.4. Precision Psychiatric Services, Inc
14.5. Tempus Labs, Inc.
14.6. Curis AI Inc.
15. STRATEGIC RECOMMENDATIONS
